Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients

Gyongyi Szabo
University of Massachusetts Medical School, gyongyi.szabo@umassmed.edu

Samir Zakhari
National Institutes of Health

Follow this and additional works at: http://escholarship.umassmed.edu/gastroenterology_pp

Part of the Digestive System Diseases Commons, Gastroenterology Commons, Immunology and Infectious Disease Commons, and the Virus Diseases Commons

Repository Citation
http://escholarship.umassmed.edu/gastroenterology_pp/122

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Gastroenterology Publications and Presentations by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients

Gyongyi Szabo, Samir Zakhari

Abstract

Clinical observations have demonstrated that excessive chronic alcohol use negatively affects human immunodeficiency virus (HIV) infection and contributes to the liver manifestations of the disease, even in HIV mono-infection. HIV/hepatitis C virus (HCV) co-infection is associated with increased progression of HVC liver disease compared to HVC infection alone, and both of these are negatively affected by alcohol use. Recent data suggest that alcohol use and HIV infection have common targets that contribute to progression of liver disease. Both HIV infection and chronic alcohol use are associated with increased gut permeability and elevated plasma levels of lipopolysaccharide; a central activator of inflammatory responses. Both alcoholic liver disease and HIV infection result in non-specific activation of innate immunity, proinflammatory cytokine cascade upregulation, as well as impaired antigen presenting cell and dendritic cell functions. Finally, alcohol, HIV and antiretroviral therapy affect hepatocyte functions, which contributes to liver damage. The common targets of alcohol and HIV infection in liver disease are discussed in this mini-review.

INTRODUCTION

The life expectancy of patients infected with human immunodeficiency virus (HIV) has been prolonged, therefore, liver diseases have assumed far greater importance as a cause of morbidity and mortality in these patients. Antiretroviral therapy (ART) used by patients who have HIV infection is often hepatotoxic. In addition, patients who have HIV often are co-infected with hepatotropic viruses such as hepatitis B and C viruses; factors that are damaging to the liver. Furthermore, chronic alcohol consumption causes injury to the liver and may result in more rapid progression to cirrhosis, end-stage liver disease, and hepatocellular carcinoma in co-infected patients. This review addresses the interactions between these factors that result in furthering liver damage.
HIV, VIRAL HEPATITIS AND ALCOHOL USE - EPIDEMIOLOGY AND NATURAL HISTORY OF LIVER DISEASE

The natural history of HIV infection has drastically changed since the discovery of its clinical manifestation, AIDS in advanced disease. HIV affects about 40 million people worldwide, with most of the infections in developing countries. As a blood-borne pathogen, HIV infection is transmitted via blood, sexual contact, and maternal-newborn transfer. HIV primarily infects immune cells and it replicates in T lymphocytes and monocytes. HIV mono-infection results in minimal hepatitis, however, coinfection with hepatitis virus results in increased liver damage. Hepatitis B virus (HBV) infection affects 370 million people and it is estimated that an additional 170 million suffer from hepatitis C virus (HCV) infection. Both HBV and HCV can lead to chronic hepatitis and as a result, progressive liver inflammation and fibrosis lead to cirrhosis and liver failure. An additional insult to the liver is excessive alcohol consumption that is an ongoing social and medical problem in people with and without HIV infection.

Several studies have found significant alcohol problems in HIV-infected individuals. In a primary care setting, physicians have reported that alcohol consumption is a common habit in patients initiating care for HIV disease. Heavy drinking among people with HIV infection under medical care has been found to be almost double that of the general population. It has also been shown that heavy alcohol consumption has a negative impact on CD4 cell count in HIV-infected persons who are not receiving ART.

The interaction of HIV and HCV infection has received increasing attention in recent years. It has been well documented that liver disease progression is accelerated in HIV/HCV co-infected patients compared with HIV or even HCV mono-infection. Furthermore, chronic heavy alcohol consumption acts as an additional insult in all of these forms of chronic hepatitis. With the new era of highly active antiretroviral therapy (HAART) that provides sufficient control of HIV replication, it has become evident that, in HIV/HCV co-infected patients, progression of HCV infection causes more lethality than HIV infection itself.

Excessive alcohol consumption is associated with fatty liver, and if persistent, it can lead to alcoholic steatohepatitis, liver fibrosis and cirrhosis. Clinical studies have demonstrated that excessive alcohol consumption in individuals with comorbid conditions such as chronic HCV or HBV infection accelerates liver damage and progression to liver cirrhosis. In a study of a large cohort of HIV-positive and negative US veterans, investigators have found a trend toward increased liver injury manifested as inflammation and fibrosis, in patients with hazardous or binge drinking. The same study has shown that alcohol abuse and dependence significantly increase the risk of advanced fibrosis and cirrhosis in HIV mono-infected patients, as well as in those with HIV/HCV co-infection. A cross-sectional study has investigated the impact of alcohol on liver fibrosis using aspartate aminotransferase (AST)-to-platelet ratio index (APRI) as a measure of liver function, and has found significant liver disease with an APRI > 1.5. This study also has found that hazardous alcohol drinking is an independent, modifiable risk factor for fibrosis, and the same investigators have concluded that the problem of alcohol abuse is not adequately addressed by health care providers in patients with HIV positivity.

In HIV-infected patients, 17% of death was related to end-stage liver disease; of those, 75% of patients had HIV/HCV co-infection and 48% heavy alcohol use history. Alcohol use in HIV-infected patients was also shown to be associated with decreased adherence to ART, and not surprisingly, reduced HIV suppression.

ALCOHOL AND HIV: COMMON TARGETS IN LIVER DISEASE

Although the pathological mechanisms of alcoholic liver disease are relatively well explored, the mechanisms by which HIV infection affects the liver remain somewhat elusive. Based on current knowledge, several elements in the pathological mechanisms of alcohol-induced liver disease can be exacerbated by HIV infection, which results in the potentiation of the individual negative effects. These major categories of mutual actions and modulating effects of both alcohol and HIV infection are on gut permeability and gut-liver homeostasis, immune functions and inflammation, and alterations in hepatocyte functions and survival (Figure 1).

Gut permeability and the role of lipopolysaccharide in HIV infection and alcoholic liver disease

The important role of gut-derived lipopolysaccharide (LPS) has been demonstrated in alcoholic liver disease in humans, as well as in animal models of chronic alcohol administration. Gut-derived LPS has been shown to have a causative role in alcoholic liver injury as demonstrated by experiments in which gut sterilization with antibiotics prevented alcohol-induced liver damage. This
was associated with increased intestinal permeability in rats\(^{30}\). Alcohol feeding in rats and mice increases serum endotoxin levels after 1-2 wk, and these increases remain after continued alcohol administration\(^{10}\). Studies in mice as well as in vitro have demonstrated that alcohol damages the intestinal epithelial barrier by downregulating tight junction proteins\(^{32-34}\). The importance of the gut-liver axis has been implicated in alcoholic liver diseases and in other etiologies of liver injury\(^{17,20}\).

The novel finding, that HIV infection is associated with increased plasma endotoxin levels was first reported by Douek’s group in 2006\(^{35}\). Plasma LPS was significantly increased in patients with chronic HIV infection, as well as in patients with AIDS compared to uninfected controls or to those with acute infection\(^{36-38}\). LPS in the serum is bound to lipoprotein binding protein (LBP) and soluble CD14 (sCD14) that modulate the biological availability of LPS. The same authors have found increased plasma sCD14 and LBP levels even in acute HIV infection, as well as in those with progressive HIV infection\(^{39}\). Subsequent studies have evaluated the effect of ART on plasma LPS levels and have found that patients with ART have a moderate decrease in plasma LPS levels\(^{40}\). This is also associated with an improvement in plasma tumor necrosis factor (TNF)\(\alpha\) levels, which suggests attenuation of inflammatory cell activation\(^{36-38}\). The source of the increased plasma LPS in HIV infection is presumably the gut. It has been speculated that HIV infection in the intestinal epithelial and immune environment permits increased translocation of gut microbiota and their components such as LPS\(^{39}\).

Increased serum LPS levels have been noted in patients with chronic HCV infection, even in the absence of advanced liver disease\(^{40}\). Furthermore, in patients with HCV and HIV co-infection, serum LPS levels are higher compared to those in patients with HIV infection alone\(^{41}\).

The biological significance of the elevated serum or plasma LPS in HIV infection is yet to be fully understood. It is generally accepted that chronic LPS exposure of immune and inflammatory cells results in a non-specific inflammation that may “reset” thresholds for specific immune responses\(^{42-45}\). It is tempting to speculate that constant and repeated exposure of innate immune cells, particularly tissue macrophages (Kupffer cells) in the liver from the gut-derived LPS in the portal blood, could result in loss of LPS tolerance, which predisposes to increased inflammatory responses\(^{43}\). We have found loss of Toll-like receptor (TLR) tolerance in circulating monocytes of HCV-infected patients, and this is associated with increased production of proinflammatory signals including TNF\(\alpha\)\(^{40}\).

In alcoholic liver disease, there is a large body of evidence in support of increased sensitivity of Kupffer cells to LPS and proinflammatory cytokine activation\(^{44,45}\) (Figure 2). Early studies have demonstrated that elimination of Kupffer cells with gadolinium chloride in rats ameliorates alcohol-induced liver damage and that LPS/CD14 receptor signaling is involved\(^{46}\). Recently, we have shown that deficiency in TLR4, the receptor for LPS, or deficiency in the TLR4 downstream signaling by interferon regulatory factor 3, are crucial for development of alcohol-induced liver damage\(^{14,46}\). The combined effect of alcohol and HIV infection on LPS signaling in the liver awaits further investigation.

**Inflammation and immune functions**

Activation of the inflammatory cascade and increased proinflammatory cytokine production is a hallmark of both alcoholic steatohepatitis and chronic HIV infection\(^{26,45}\). The immunological consequences of such proinflammatory cascade activation are not fully understood. The clinical observations of increased susceptibility to infections in alcoholic steatohepatitis and chronic HIV infection demonstrate that, although non-specific proinflammatory activation is present, pathogen-specific innate immune responses are defective. Furthermore, antigen-specific immune responses as well as antigen presenting function of monocytes and dendritic cells are severely dampened by alcohol exposure, as well as in chronic HIV infection\(^{47-49}\). Our previous studies have demonstrated that acute alcohol consumption in humans inhibits the antigen presenting function in human monocyte-derived dendritic cells and monocytes \textit{via} mechanisms that involve decreased interleukin (IL)-12 and co-stimulatory molecule expression and/or impaired dendritic cell differentiation/maturation\(^{48-51}\). The effects of prolonged alcohol also inhibit myeloid dendritic cell functions in humans as well as mouse models\(^{51}\).

Defects in myeloid and plasmacytoid dendritic cell function have been extensively studied in HIV infection. It has been shown that HIV infection results in impaired differentiation and maturation of monocyte-derived dendritic cells in humans and that these dendritic cells have impaired antigen presentation capacity. Chronic HCV infection is also associated with decreased antigen presenting function of dendritic cells and HIV and HCV infection affect im-
Table 1  Common mechanisms of liver/hepatocyte damage

<table>
<thead>
<tr>
<th>Effect</th>
<th>HIV</th>
<th>HCV</th>
<th>Alcohol</th>
<th>HAART</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increase ROS</td>
<td>√</td>
<td>√</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Increase proinflammatory cytokines</td>
<td>√</td>
<td>√</td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Oxidative stress</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipid peroxidation</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondrial damage</td>
<td>√</td>
<td></td>
<td></td>
<td>√</td>
</tr>
<tr>
<td>Steatosis</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutathione depletion</td>
<td>√</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proteasome dysfunction</td>
<td></td>
<td></td>
<td></td>
<td>√</td>
</tr>
</tbody>
</table>

HIV: Human immunodeficiency virus; HCV: Hepatitis C virus; HAART: Highly active antiretroviral therapy; ROS: Reactive oxygen species.

Table 1  Common mechanisms of liver/hepatocyte damage

Hepatocyte function and cell death

There are multiple mechanisms by which HIV infection and even ART could directly affect hepatocytes. As summarized in Table 1, reactive oxygen radical production, mitochondrial damage and steatosis can all be induced independently by alcohol, HIV or HCV infections alone or in combination with HAART[64]. However, these factors together will most likely cause combined damage in exposed hepatocytes. Some of the mechanisms involved include depletion of the intracellular glutathione stores by chronic alcohol and HIV infection that predisposes to increased reactive oxygen species (ROS) production and increased susceptibility to hepatocyte death[53]. In addition, alcohol, HCV, and HAART cause mitochondrial damage, fatty liver, and increased levels of proinflammatory cytokines, particularly, TNFα, which results in hepatocyte death. This mechanism has been investigated in alcoholic liver damage as well as in HIV infection, and HIV/HCV co-infection[65].

Although the introduction of HAART for HIV infection has resulted in a significant decrease in the mortality rate of AIDS, a sizable proportion of patients receiving HAART develop liver toxicity. For example, patients treated with the antiretroviral nucleoside reverse-transcriptase inhibitors (NRTIs) zidovudine, zalcitabine, didanosine and stavudine have been reported to develop hepatic steatosis[66-69]. Heavy alcohol consumption by HIV patients on HAART[70] results in liver decomposition in about 2% of cases[71], and increases the risk of liver injury 5.8 times in 10% of patients receiving NRTI or non-NRTI regimens[72]. The enhanced liver toxicity due to alcohol, HCV, and HAART could result from shared mechanisms such as fat accumulation and mitochondrial damage.

Fat accumulation and insulin resistance

Alcohol and HCV-induced fatty liver is well documented. Several mechanisms have been reported for alcohol-induced fatty liver including increased hepatic uptake of fatty acids and de novo lipogenesis, impaired peroxisome proliferator-activated receptor α signaling, reduced mitochondrial fatty acid oxidation and reduced secretion of triglycerides[66-68]. These effects could be attributed to reduced adiponectin secretion by the adipose tissue and elevated expression of TNFα[65-67].

Some AIDS patients develop HAART-associated lipodystrophy (LD). A study by Sutinen and co-workers[73] has shown that, in comparison to HIV-negative subjects, HAART+LD patients show: (1) higher liver fat content (regardless of alcohol consumption); (2) for a given amount of liver fat, serum-free insulin concentration correlated with liver fat, which suggests that fat accumulation in the liver is crucial for development of insulin resistance; and (3) significantly lower leptin concentrations than the other two groups. Others have also demonstrated low plasma leptin concentrations in patients with HAART-associated LD[69]. Hypoleptinemia and subsequent insulin resistance could favor fatty liver accumulation in patients suffering from NRTI-induced lipodystrophy[70,71].

Although Sutinen and co-workers did not observe lactic acidosis, others have reported lactic acidosis and hepatic steatosis in some patients using HAART, which was attributed to mitochondrial toxicity induced by nucleoside analogs[70-71]. In addition, co-infection with HCV increases the risk for severe liver damage during HAART[72,73], and end-stage liver disease is the primary cause of death in HIV/HCV co-infected patients under HAART[74,75]. Seth[76] has reported that, in HIV co-infected patients, the HCV load is higher by an average of 0.5-1.0 log than the mono-infected patients due to immune depression. Studies on liver fibrosis show conflicting results. Although some studies have found that early HAART in HIV/HCV co-infected patients may slow liver fibrosis progression[77], others have found that HAART regimens including nevirapine accelerate liver fibrosis progression in HIV/HCV co-infected patients[78].

Mitochondrial damage

Alcohol and HCV can induce mitochondrial DNA (mtDNA) damage through the production of ROS and/or reactive metabolites. It has been reported that prolonged administration of antiretroviral NRTIs increases the risk of mitochondrial damage in the liver[79,80]. NRTIs can cause the accumulation of the oxidized base 8-hydroxydeoxyguanosine (8-OH-dG) in liver mtDNA[79,80]. In addition, NRTIs can cause mtDNA point mutations in some patients, which may result from interaction with mtDNA replication (via misreading of 8-OH-dG by DNA polymerase c) and/or impairment of polymerase c repair capacity[81,82]. It has been reported that NRTIs inhibit mtDNA replication by
undergoing phosphorylation as the cognate endogenous nucleosides, which are subsequently incorporated within the mitochondrial genome by DNA polymerase c.\(^{[81]}\)

**CONCLUSION**

Although increasing evidence suggests enhanced combined effects of alcohol and HIV infection on the liver with and without viral hepatitis, a number of questions remain unanswered. What are the interactions between alcohol use, HIV, HCV and HBV infections? Is the cross-talk between organs, such as the homeostasis between the liver and gut, affected by combined insults of alcohol, HIV and viral hepatitis? What is the effect of the cumulative effects of alcohol and HIV infection on cross-regulation between various cell types in the liver? How can new therapeutic targets be developed in the light of knowledge about the interactive effects of HIV and alcohol on the liver? All of these questions are pertinent to the status and defects observed in immune functions, gut permeability, Kupffer cell activation, hepatocyte function and liver fibrosis/stellate cell function in patients with HIV infection and excessive alcohol use and/or viral hepatitis.

**REFERENCES**

24. Immune mechanisms in alcoholic liver disease. *Genes Nutr 2009; Epub ahead of print
30. Keshavarzian A, Farhadi A, Forsyth CB, Rangan J, Jakate S, Shaikh M, Banan A, Fields JZ. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hy-
permeability and endothoxemia prior to development of alcoholic steatohepatitis in rats. *J Hepatol* 2009; 50: 538-547


38 Trosed M, Nowak P, Nystrom J, Lindkvist A, Abdurahman S, Sonnenborg A. Elevated plasma levels of lipopolysaccharide and high mobility group box-1 protein are associated with high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. *AIDS* 2010; 24: 1733-1737


41 Baum M, Sales S, Jayaweera D, Lai S, Bradwin G, Rafie C, Page J, Campa A. Coinfection with hepatitis C virus, oxida


49 Donaghy H, Stebbing J, Patterson S. Antigen presentation and the role of dendritic cells in HIV. *Curr Opin Infect Dis* 2004; 17: 1-6


53 Kim AY, Chung RT. Coinfection with HIV-1 and HCV—a one-two punch. *Gastroenterology* 2009; 137: 797-804

tory capacity by alcohol and hepatitis C is not restored by DC maturation and involves abnormal IL-10 and IL-2 induction. *Alcohol Clin Exp Res* 2003; 27: 1023-1031

55 Núñez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V. Risk factors for severe hepatic injury after introduc
tion of highly active antiretroviral therapy. *J Acquir Immune Defic Syndr 2001; 27: 426-431


57 Le Bras P, D’Oiro R, Quertainmont Y, Hafon P, Caquet R. Metabolic, hepatic and muscular changes during zidovu


59 Crabb DW, Galli A, Fischer M, You M. Molecular mecha
nisms of alcoholic fatty liver: role of peroxisome proliferator-activated receptor alpha. *Alcohol* 2004; 34: 35-38

60 Donohue TM. Alcohol-induced steatosis in liver cells. *World J Gastroenterol* 2007; 13: 4974-4978

61 Ji C, Chan C, Kaplowitz N. Predominant role of sterol re
sponse element binding proteins (SREBP) lipogenic path
ways in hepatic steatosis in the murine intragastric ethanol feeding model. *J Hepatol* 2006; 45: 717-724

62 Song Z, Zhou Z, Dacuic I, Chen T, McClain CJ. Inhibition of adipo
tenone production by homocysteine: a potential mecha
nism for alcoholic liver disease. *Hepatology* 2008; 47: 867-879

63 Chen X, Sebastian BM, Tang H, McMullen MM, Ashemi A, Jacobsen DW, Nagy L. Taurine supplementation prevents ethanol-induced decrease in serum adipo
tenone and reduces hepatic steatosis in rats. *Hepatology* 2009; 49: 1554-1562

64 Zeng T, Xie KQ. Ethanol and liver: recent advances in the mechanisms of ethanol-induced hepatotoxicity. *Arch Toxicol* 2009; 83: 1075-1081


pose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral thera

67 Igoujdji A, Abbey-Toby A, Begrich K, Grodet A, Chataign-


75 Seth AK. Management of hepatitis C in HIV infected and other immunocompromised individuals. Trop Gastroenterol 2006; 27: 111-117


S-Editor Tian L L-Editor Kerr C E-Editor Ma WH